Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Contracts + Grants

    US Army Special Immunizations Program for Rift Valley Fever Vaccine

    By Global Biodefense StaffMay 25, 2017
    Biodefense Request for Information (RFI)
    Share
    Facebook LinkedIn Reddit Email

    The U.S. Army Medical Research and Materiel Command (USAMRMC) Special Immunizations Program (SIP) currently offers Investigational New Drug (IND) products to both military and civilian personnel at risk for pathogen and toxin exposure.

    The current portfolio of SIP vaccines consists of legacy products produced primarily by the Salk Institute in the 1960’s to the 1980’s that are not on a path for FDA licensure. There is a current need to have one of these vaccines, originally vialed in multi-dose format, re-vialed into single-dose vials.

    MP-12 is a live-attenuated vaccine developed to produce a protective immune response against Rift Valley Fever Virus (RVF), a virus endemic to sub-Saharan Africa. The vaccine is a lyophilized, IND product produced by The Salk Institute Government Services Division (TSI-GSD) in the nineteen eighties.

    The SIP is looking for a facility with sterile fill-finish and lyophilization capability to re-vial between 250 and 1000 20 mL vials to single-dose vials (5000-20000 vials). The number of vaccine vials processed will be specified at a later time and will depend on capacity of the facility, cost, and needs of the product sponsor.

    The facility should indicate the capability to perform, support, or otherwise arrange for lot-release and stability testing that could include sterility, endotoxin, mycoplasma, potency (virus titer measurement by plaque assay), and other assays as agreed upon.

    Further details are available via Solicitation Number: W81XWH-RFI-SIP2. The response deadline is Jun 05, 2017 4:00 pm Eastern.

    RFI Rift Valley Fever Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleDHS Seeks Capabilities in Advanced Pathogen Characterization and Predictive Analytics
    Next Article Enhancing the Efficacy of Adenovirus-5 Vectored Ebola Virus Vaccines

    Related Stories

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Human BCG Challenge Model for Assessment of Tuberculosis Immunity

    December 2, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.